Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




First-Trimester Blood Test Accurately Predicts Gestational Diabetes

By LabMedica International staff writers
Posted on 22 Aug 2025

Gestational diabetes mellitus (GDM) affects many pregnancies and is typically detected midway through pregnancy, often too late to prevent complications. More...

Women diagnosed late face increased risks such as high blood pressure, large babies, and premature delivery. The condition is also linked to lifelong risks of type 2 diabetes and heart disease for both mothers and their children. Now, a new study shows that specific maternal biomarkers taken from first-trimester random blood samples can significantly improve early prediction of GDM risk.

The study by researchers from the Global Centre for Asian Women’s Health (GloW, Singapore) and the National University of Singapore (NUS Medicine, Singapore) analyzed selected maternal biomarkers from first-trimester random blood samples to test their predictive value. The findings, published in BMC Medicine, showed that seven specific first-trimester biomarkers significantly improved GDM risk prediction beyond conventional factors like maternal age, pre-pregnancy BMI, and family history of diabetes.

Importantly, the predictive performance of these first-trimester biomarkers matched that of those taken from second-trimester fasting blood samples. This strong ability to distinguish between high-risk and low-risk pregnancies demonstrates their clinical usefulness and opens a pathway for earlier interventions.

Early and effective GDM screening could become increasingly important as maternal age and obesity rates continue to rise across Asia, driving higher numbers of affected women. By enabling earlier identification of risk, women can adopt timely nutrition and lifestyle changes to prevent complications during pregnancy. Moreover, early interventions could also reduce the likelihood of mothers and children developing type 2 diabetes or cardiovascular disease later in life.

Related Links:
GloW
NUS Medicine 


New
Gold Member
Automatic Hematology Analyzer
DH-800 Series
Collection and Transport System
PurSafe Plus®
New
Gold Member
Automatic Chemiluminescence Immunoassay Analyzer
Shine i2000
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The tool enables scientists to track real-time fluctuations in T cell function with unprecedented speed and precision (Photo courtesy of Shutterstock)

Luminescent Probe Measures Immune Cell Activity in Real Time

The human immune system plays a vital role in defending against disease, but its activity must be precisely monitored to ensure effective treatment in cancer therapy, autoimmune disorders, and organ transplants.... Read more

Industry

view channel
Image: The collaboration supports clinical validation and regulatory submissions of the new T1D 4-plex assay on Revvity’s GSP instrument (Photo courtesy of Revvity)

Revvity and Sanofi Collaborate on Program to Revolutionize Early Detection of Type 1 Diabetes

Type 1 diabetes (T1D) is a lifelong autoimmune condition in which the immune system destroys the pancreas’s insulin-producing beta cells, leading to dependence on insulin therapy. Early detection is critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.